Pakistan · Delayed Price · Currency is PKR BF Biosciences Statistics
Total Valuation
BF Biosciences has a market cap or net worth of PKR 11.14 billion. The enterprise value is 12.18 billion.
| Market Cap | 11.14B |
| Enterprise Value | 12.18B |
Important Dates
The last earnings date was Monday, September 28, 2026.
| Earnings Date | Sep 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BF Biosciences has 88.33 million shares outstanding. The number of shares has increased by 9.14% in one year.
| Current Share Class | 88.33M |
| Shares Outstanding | 88.33M |
| Shares Change (YoY) | +9.14% |
| Shares Change (QoQ) | -0.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.58% |
| Float | 25.00M |
Valuation Ratios
The trailing PE ratio is 17.98.
| PE Ratio | 17.98 |
| Forward PE | n/a |
| PS Ratio | 1.20 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 19.62 |
| EV / Sales | 1.31 |
| EV / EBITDA | 9.12 |
| EV / EBIT | 11.41 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.93, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.93 |
| Quick Ratio | 0.42 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 1.19 |
| Debt / FCF | n/a |
| Interest Coverage | 12.52 |
Financial Efficiency
Return on equity (ROE) is 12.70% and return on invested capital (ROIC) is 10.47%.
| Return on Equity (ROE) | 12.70% |
| Return on Assets (ROA) | 7.84% |
| Return on Invested Capital (ROIC) | 10.47% |
| Return on Capital Employed (ROCE) | 15.81% |
| Weighted Average Cost of Capital (WACC) | 3.09% |
| Revenue Per Employee | 11.10M |
| Profits Per Employee | 741,933 |
| Employee Count | 852 |
| Asset Turnover | 1.09 |
| Inventory Turnover | 2.25 |
Taxes
In the past 12 months, BF Biosciences has paid 435.28 million in taxes.
| Income Tax | 435.28M |
| Effective Tax Rate | 40.78% |
Stock Price Statistics
The stock price has decreased by -20.42% in the last 52 weeks. The beta is -0.21, so BF Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | -20.42% |
| 50-Day Moving Average | 128.58 |
| 200-Day Moving Average | 140.02 |
| Relative Strength Index (RSI) | 48.74 |
| Average Volume (20 Days) | 193,423 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BF Biosciences had revenue of PKR 9.46 billion and earned 632.13 million in profits. Earnings per share was 7.16.
| Revenue | 9.46B |
| Gross Profit | 4.08B |
| Operating Income | 1.09B |
| Pretax Income | 1.07B |
| Net Income | 632.13M |
| EBITDA | 1.36B |
| EBIT | 1.09B |
| Earnings Per Share (EPS) | 7.16 |
Balance Sheet
The company has 572.77 million in cash and 1.61 billion in debt, with a net cash position of -1.04 billion or -11.78 per share.
| Cash & Cash Equivalents | 572.77M |
| Total Debt | 1.61B |
| Net Cash | -1.04B |
| Net Cash Per Share | -11.78 |
| Equity (Book Value) | 5.29B |
| Book Value Per Share | 59.93 |
| Working Capital | 2.14B |
Cash Flow
In the last 12 months, operating cash flow was -26.51 million and capital expenditures -603.06 million, giving a free cash flow of -629.57 million.
| Operating Cash Flow | -26.51M |
| Capital Expenditures | -603.06M |
| Depreciation & Amortization | 273.58M |
| Net Borrowing | -236.31M |
| Free Cash Flow | -629.57M |
| FCF Per Share | -7.13 |
Margins
Gross margin is 43.08%, with operating and profit margins of 11.49% and 6.68%.
| Gross Margin | 43.08% |
| Operating Margin | 11.49% |
| Pretax Margin | 11.28% |
| Profit Margin | 6.68% |
| EBITDA Margin | 14.38% |
| EBIT Margin | 11.49% |
| FCF Margin | n/a |
Dividends & Yields
BF Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.14% |
| Shareholder Yield | -9.14% |
| Earnings Yield | 5.56% |
| FCF Yield | -5.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BF Biosciences has an Altman Z-Score of 4.29 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.29 |
| Piotroski F-Score | 5 |